Results 241 to 250 of about 50,964 (281)
Some of the next articles are maybe not open access.
Satraplatin for the Therapy of Castration-Resistant Prostate Cancer
Future Oncology, 2009While docetaxel-based chemotherapy improves survival in patients with castration-resistant prostate cancer, all of these patient's cancers will eventually progress and other active treatment agents are necessary. Satraplatin is a third-generation orally-available platinum analog that demonstrated a 33% reduction in the risk of progression in patients ...
Guru, Sonpavde, Cora N, Sternberg
openaire +2 more sources
Leading causes of castration-resistant prostate cancer
Expert Review of Anticancer Therapy, 2015Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling.
Mingqian, Lu, Hongda, Lu, Qingzhi, Kong
openaire +2 more sources
Sequential Therapies in Castration-Resistant Prostate Cancer
Future Oncology, 2014153 ISSN 1479-6694 10.2217/FON.13.243 © 2014 Future Medicine Ltd Future Oncol. (2014) 10(2), 153–155 An unprecedented large number of agents capable of prolonging survival is presently available for patients with castrationresistant prostate cancer (CRPC) [1,2].
Carlo, Buonerba, Giuseppe, Di Lorenzo
openaire +2 more sources
Advances in the management of castration resistant prostate cancer
BMJ, 2016Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel ...
Chad R, Ritch, Michael S, Cookson
openaire +2 more sources
Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
Future Oncology, 2010Treatment with docetaxel-based chemotherapy results in improved survival in patients with metastatic castration-resistant prostate cancer. However, all patients eventually develop progressive disease associated with poor outcomes. In this article, we discuss the available second-line therapeutic options following docetaxel, with a special focus on ...
Neeraj, Agarwal +2 more
openaire +2 more sources
Palliative Care in Castrate-Resistant Prostate Cancer
Urologic Clinics of North America, 2012Significant symptoms and suffering related to castrate-resistant prostate cancer (CRPC) are associated with the disease and its treatment. Increasingly, with advances in treatment efficacy, men can live with symptoms for long periods. Interdisciplinary palliative care teams (including physicians, nurses, social workers, chaplains, pharmacists ...
Michael W, Rabow, Michael Xiang, Lee
openaire +2 more sources
Management of nonmetastatic castration-resistant prostate cancer
Current Opinion in Supportive & Palliative Care, 2018Purpose of review The widespread use of prostate-specific antigen (PSA) resulted in stage migration of prostate cancer where androgen deprivation therapy (ADT) is administered for biochemical recurrence in patients following primary treatment.
Samer L, Traboulsi, Fred, Saad
openaire +2 more sources
Castration-Resistant Prostate Cancer: AUA Guideline
Journal of Urology, 2013This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data.A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate ...
Michael S, Cookson +11 more
openaire +2 more sources
Enzalutamide in Castration-Resistant Prostate Cancer
New England Journal of Medicine, 2018Giacomo, Bregni +2 more
openaire +4 more sources
Olaparib for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine, 2020Bivas, Biswas +2 more
openaire +8 more sources